EULAV Asset Management Cuts Stock Holdings in Stryker Corporation $SYK

Posted by Francis Steltz on Jun 6th, 2026

EULAV Asset Management decreased its stake in shares of Stryker Corporation (NYSE:SYK – Free Report) by 16.4% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 101,813 shares of the medical technology company’s stock after selling 20,000 shares during the period. EULAV Asset Management’s holdings in Stryker were worth $35,784,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. United Financial Planning Group LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $27,000. Godfrey Financial Associates Inc. purchased a new position in shares of Stryker during the fourth quarter valued at approximately $26,000. Strive Asset Management LLC purchased a new position in shares of Stryker during the third quarter valued at approximately $30,000. CGC Financial Services LLC purchased a new position in shares of Stryker during the fourth quarter valued at approximately $29,000. Finally, ANTIPODES PARTNERS Ltd purchased a new position in shares of Stryker during the third quarter valued at approximately $34,000. Hedge funds and other institutional investors own 77.09% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently issued reports on SYK shares. Leerink Partners reduced their target price on Stryker from $410.00 to $407.00 and set an “outperform” rating for the company in a report on Friday. Robert W. Baird set a $385.00 target price on Stryker in a report on Friday, May 1st. Wells Fargo & Company reduced their target price on Stryker from $456.00 to $418.00 and set an “overweight” rating for the company in a report on Friday, May 1st. Barclays reduced their target price on Stryker from $469.00 to $394.00 and set an “overweight” rating for the company in a report on Monday, May 4th. Finally, Canaccord Genuity Group reduced their target price on Stryker from $435.00 to $400.00 and set a “buy” rating for the company in a report on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $395.33.

Check Out Our Latest Stock Report on Stryker

Insider Activity at Stryker

In other Stryker news, Director Ronda E. Stryker sold 310,000 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $312.23, for a total transaction of $96,791,300.00. Following the sale, the director owned 1,924,880 shares in the company, valued at $601,005,282.40. This represents a 13.87% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, VP M Kathryn Fink sold 5,220 shares of the stock in a transaction on Monday, May 11th. The stock was sold at an average price of $283.85, for a total value of $1,481,697.00. Following the sale, the vice president owned 13,137 shares in the company, valued at approximately $3,728,937.45. This represents a 28.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 323,264 shares of company stock worth $100,659,489. Insiders own 4.60% of the company’s stock.

Stryker Price Performance

Stryker stock opened at $305.71 on Friday. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62. The business’s 50 day simple moving average is $318.43 and its 200 day simple moving average is $345.86. The company has a market cap of $117.20 billion, a price-to-earnings ratio of 35.38, a PEG ratio of 1.90 and a beta of 0.78.

Stryker (NYSE:SYK – Get Free Report) last posted its quarterly earnings data on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing the consensus estimate of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $6.34 billion. During the same quarter in the previous year, the company posted $2.84 EPS. Stryker’s revenue for the quarter was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. Sell-side analysts forecast that Stryker Corporation will post 14.98 EPS for the current year.

Stryker Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Investors of record on Tuesday, June 30th will be paid a $0.88 dividend. The ex-dividend date is Tuesday, June 30th. This represents a $3.52 annualized dividend and a yield of 1.2%. Stryker’s dividend payout ratio is presently 40.74%.

Stryker Company Profile

(Free Report)

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.